Science
Hong Jae Chon: Indirect Comparison of First-Line HCC Combination Therapies
Hong Jae Chon/X

Hong Jae Chon: Indirect Comparison of First-Line HCC Combination Therapies

Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared on X:

“No head-to-head trials compare first-line HCC combo therapies.

Researchers reconstructed patient data from KM curves (IPDfromKM) to rank them indirectly.

New analysis in World J Gastrointest Pharmacol Ther (8 phase III RCTs)

  • vs sorafenib: camrelizumab + rivoceranib had the best HR (0.61); cabozantinib+atezolizumab showed no benefit
  • vs lenvatinib: nivolumab+ipilimumab and pembrolizumab+lenvatinib showed modest, similar gains

Comparator choice (sorafenib vs lenvatinib) shapes the results – a descriptive, not causal, ranking.”

Title: Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan–Meier curves of randomized trials

Authors: Vera Damuzzo, Stefano Vecchia, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Elena Orlandi, Andrea Messori

Read the Full Article

Hong Jae Chon

Other articles featuring Hong Jae Chon on OncoDaily.

Andrea Messori Andrea Ossato atezolizumab Cabozantinib Camrelizumab cancer Elena Orlandi HCC Hong Jae Chon ipilimumab Lenvatinib Lorenzo Gasperoni Luna Del Bono nivolumab OncoDaily Oncology pembrolizumab rivoceranib sorafenib Stefano Vecchia Vera Damuzzo